{
    "nct_id": "NCT04270942",
    "official_title": "An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes",
    "inclusion_criteria": "1. Previous participant in the TN-10 study\n2. Participant had received a diagnosis of type 1 diabetes after the conclusion of the TN-10 study, according to the criteria from the American Diabetes Association (ADA).\n3. Participant was able to initiate teplizumab treatment required in this study within 1 year of type 1 diabetes diagnosis.\n4. Participant was willing to forego other forms of experimental treatment during the entire study.\n5. Participant and/or guardian had given informed consent and assent as applicable.\nHealthy volunteers allowed",
    "exclusion_criteria": "1. Had an active infection and/or fever.\n2. Had a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).\n3. An individual who had a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.",
    "miscellaneous_criteria": ""
}